http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21382882

Outgoing Links

Predicate Object
contentType Journal Article|Review
endingPage 855
issn 1354-3784
1744-7658
issueIdentifier 8
pageRange 843-855
publicationName Expert Opinion on Investigational Drugs
startingPage 843
bibliographicCitation Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opinion on Investigational Drugs. 2006 Jul 21;15(8):843–55. doi: 10.1517/13543784.15.8.843.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_776277bd999cdc9acbc16bca66aaffad
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ccdbeb5e5c55658098c73b93d9182dfc
date 2006-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1517/13543784.15.8.843
https://pubmed.ncbi.nlm.nih.gov/16859389
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21889
https://portal.issn.org/resource/ISSN/1744-7658
https://portal.issn.org/resource/ISSN/1354-3784
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases
discusses http://id.nlm.nih.gov/mesh/M0014459
http://id.nlm.nih.gov/mesh/M0458117
http://id.nlm.nih.gov/mesh/M0571969
http://id.nlm.nih.gov/mesh/M0501463
http://id.nlm.nih.gov/mesh/M0021371
http://id.nlm.nih.gov/mesh/M0017759
http://id.nlm.nih.gov/mesh/M0015281
http://id.nlm.nih.gov/mesh/M0014072
http://id.nlm.nih.gov/mesh/M0001380
http://id.nlm.nih.gov/mesh/M0024399
http://id.nlm.nih.gov/mesh/M0403648
http://id.nlm.nih.gov/mesh/M0017249
http://id.nlm.nih.gov/mesh/M0587609
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D065427
http://id.nlm.nih.gov/mesh/D013923Q000188
http://id.nlm.nih.gov/mesh/D011134Q000627
http://id.nlm.nih.gov/mesh/D000925Q000627
hasSubjectTerm http://id.nlm.nih.gov/mesh/D016032
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D013923Q000517
http://id.nlm.nih.gov/mesh/D009025Q000627
http://id.nlm.nih.gov/mesh/D009025Q000008
http://id.nlm.nih.gov/mesh/D000925Q000008
http://id.nlm.nih.gov/mesh/D011134Q000008
http://id.nlm.nih.gov/mesh/D013876Q000627
http://id.nlm.nih.gov/mesh/D009844Q000008
http://id.nlm.nih.gov/mesh/D000069552
http://id.nlm.nih.gov/mesh/D000284
http://id.nlm.nih.gov/mesh/D013876Q000008
http://id.nlm.nih.gov/mesh/D000077425
http://id.nlm.nih.gov/mesh/D009844Q000627
http://id.nlm.nih.gov/mesh/D007275
http://id.nlm.nih.gov/mesh/D007279
http://id.nlm.nih.gov/mesh/D000818
http://id.nlm.nih.gov/mesh/D015951Q000378
http://id.nlm.nih.gov/mesh/D009281Q000008
http://id.nlm.nih.gov/mesh/D013923Q000378
http://id.nlm.nih.gov/mesh/D011422Q000008
http://id.nlm.nih.gov/mesh/D011422Q000627
http://id.nlm.nih.gov/mesh/D009281Q000627
http://id.nlm.nih.gov/mesh/D001777Q000187
http://id.nlm.nih.gov/mesh/D001780
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9410
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6994
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.21.6
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282448
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3083445
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10602
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5496659
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9912771
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11071
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284607
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID122128
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280483
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4812
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9875401
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3083444
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID156594090
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9939865

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247135819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247651955
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID244491953
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248153327

Total number of triples: 84.